Elizabeth Lopatto
Bloomberg
November 13, 2009
Batches of Genzyme Corp.’s treatments for rare genetic disorders may be contaminated with steel fragments, non-latex rubber, and fiber-like materials from the manufacturing process, according to U.S. regulators.
Medicines affected include...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.